The Global Cutaneous & Systemic Leishmaniasis Market value is projected to exceed US$ 411.1 million by the year 2028 at a steady CAGR of 2.90%. The increasing prevalence of Cutaneous & Systemic Leishmaniasis in tropical regions and the growing awareness regarding prevention and treatment of the disease are the major factors driving the growth of this market.
Leishmaniasis is a parasitic disease caused by the Leishmania parasite, which is transmitted through the bite of infected sandflies. The disease can manifest in two main forms: cutaneous leishmaniasis (CL) and systemic leishmaniasis (SL). Cutaneous leishmaniasis primarily affects the skin, while systemic leishmaniasis affects multiple organs, including the spleen, liver, and bone marrow. This report aims to provide an overview of the cutaneous and systemic leishmaniasis market, including its current status, key players, treatment options, and future prospects.
Click on the link for sample report: https://www.persistencemarketresearch.com/samples/28225
Market Overview:
The global cutaneous and systemic leishmaniasis market has been witnessing steady growth over the years. The increasing prevalence of leishmaniasis in various regions, particularly in tropical and subtropical areas, is a major driver for market growth. According to the World Health Organization (WHO), leishmaniasis affects around 1.3 million people globally, with an estimated 20,000 to 30,000 deaths annually.
Drivers and Restraints:
Drivers:
- Increasing incidence of leishmaniasis: Cutaneous and systemic leishmaniasis continue to be a significant public health issue in many regions of the world, especially in tropical and subtropical areas. The rising incidence of leishmaniasis is a key driver for the market, as it creates a growing patient pool in need of diagnosis, treatment, and management.
- Lack of effective preventive measures: Currently, there are no effective vaccines available for leishmaniasis. This lack of preventive measures necessitates the development and availability of effective treatment options, driving the demand for drugs and therapies to combat the disease.
Restraints:
- Limited treatment options: The current treatment options for leishmaniasis, including antimonials, amphotericin B, and miltefosine, have limitations such as toxicity, long treatment duration, and the emergence of drug-resistant strains. The limited availability of effective and safe treatment options poses a challenge to market growth.
- High treatment cost: Some of the existing treatment options for leishmaniasis, such as liposomal amphotericin B, can be costly, making them less accessible in resource-limited settings. The high treatment cost acts as a barrier to widespread adoption and hampers market growth.
Key Companies:
- Gilead Sciences, Inc.
- Profounda Pharmaceuticals
- Knight Therapeutics Inc.
- Janssen Global Services, LLC
- Albert David Ltd
- Jubilant Life Sciences Ltd.
- Novartis AG
- Sanofi
- Endo Pharmaceuticals Inc
- Bristol-Myers Squibb Company
- United Biotech Pvt. Ltd.
Click on the link for customized report: https://www.persistencemarketresearch.com/request-customization/28225
Segmentation:
Cutaneous & Systemic Leishmaniasis Market by By Drug Class
- Pentavalent Antimonials
- Antifungal Drugs
- Anti-Lesihmanial/Antimicrobial Drugs
Cutaneous & Systemic Leishmaniasis Market By Route of Administration
- Oral
- Injectable
- Topical
Cutaneous & Systemic Leishmaniasis Market By Indication
- Cutaneous Leishmaniasis
- Mucosal Leishmaniasis
- Visceral Leishmaniasis
Cutaneous & Systemic Leishmaniasis Market By Distribution Channel
- Hospital Pharmacies,
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Cutaneous & Systemic Leishmaniasis Market by Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
Click on the link to access the full report: https://www.persistencemarketresearch.com/checkout/28225
Related Reports –
About us:
Persistence Market Research’s Expertise in Life Sciences and Transformational Health Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353